Impact of HPV Subtypes on Prognosis and Treatment in Oropharyngeal Cancers
DOI:
https://doi.org/10.63682/jns.v13i1.8422Keywords:
HPV subtypes, oropharyngeal cancer, HPV-16, p16 expression, prognosis, treatment response, survival outcomesAbstract
Background: Human papillomavirus (HPV) has been established as one of the significant causal factors for oropharyngeal squamous cell carcinoma (OPSCC). Although prognosis is usually favorable with HPV positivity, it appears that subtype variations may impact outcomes. To assess the impact of different HPV subtypes on clinical outcomes, treatment response, and survival in patients diagnosed with oropharyngeal cancers.
Methods: An observational study was carried out between March 2023 and August 2024 with a sample of 81 HPV-positive OPSCC patients. The patients were classified into three groups according to the HPV subtypes as HPV-16, HPV-18, and other high-risk variants. The study analyzed several variables such as demographics, clinical characteristics , treatment received, and outcomes after one year.
Results: HPV-16 was the most frequently occurring subtype (53.1%). Patients positive for HPV-16 showed remarkable one-year overall survival (OS) and disease-free survival (DFS) rates of 95.3% and 90.7% respectively compared to those with HPV-18 or other subtypes (p < 0.05). Responders achieving complete treatment response were also the highest in the HPV-16 group while non-HPV-16 cases experienced higher incidences of recurrence and treatment related toxicity. p16 positivity was mostly to HPV-16.
Conclusion: HPV subtype plays a critical role in shaping prognosis and treatment outcomes in oropharyngeal cancer. HPV-16 is associated with superior survival and response, suggesting the potential for subtype-specific treatment strategies to improve outcomes
Downloads
References
Sharkey Ochoa, I., et al., The role of HPV in determining treatment, survival, and prognosis of head and neck squamous cell carcinoma. Cancers, 2022. 14(17): p. 4321.
Ziai, H., et al., Does HPV subtype predict outcomes in head and neck cancers? International Journal of Otolaryngology, 2021. 2021(1): p. 6672373.
Lim, Y.X., et al., Clinical, morphologic and molecular heterogeneity of HPV-associated oropharyngeal cancer. Oncogene, 2023. 42(40): p. 2939-2955.
Shenker, R.F., et al., Clinical outcomes of oropharyngeal squamous cell carcinoma stratified by human papillomavirus subtype: a systematic review and meta-analysis. Oral oncology, 2024. 148: p. 106644.
Lechner, M., et al., HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nature reviews Clinical oncology, 2022. 19(5): p. 306-327.
Deutsch, F., et al., Current state of play for HPV-positive oropharyngeal cancers. Cancer Treatment Reviews, 2022. 110: p. 102439.
Garset‐Zamani, M., et al., Impact of specific high‐risk human papillomavirus genotypes on survival in oropharyngeal cancer. International journal of cancer, 2022. 150(7): p. 1174-1183.
Qin, T., et al., Molecular tumor subtypes of HPV-positive head and neck cancers: biological characteristics and implications for clinical outcomes. Cancers, 2021. 13(11): p. 2721.
Zeng, P.Y., et al., Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification. EBioMedicine, 2022. 86.
Skovvang, A., et al., The impact of HPV genotypes on survival in HPV-positive oropharyngeal squamous cell carcinomas: a systematic review. Acta Oto-Laryngologica, 2021. 141(7): p. 724-728.
Mehanna, H., et al., Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis. The Lancet Oncology, 2023. 24(3): p. 239-251.
Preissner, S.H., et al., Influence of sex on survival rates of HPV-positive oropharyngeal cancers. Frontiers in Oncology, 2022. 12: p. 917890.
Shenker, R.F., et al., Comparing outcomes for patients with Human Papillomavirus (HPV) type 16 versus other high-risk HPV types in oropharyngeal squamous cell carcinoma. Head and Neck Pathology, 2021: p. 1-9.
Sahovaler, A., et al., Survival outcomes in human papillomavirus–associated nonoropharyngeal squamous cell carcinomas: a systematic review and meta-analysis. JAMA Otolaryngology–Head & Neck Surgery, 2020. 146(12): p. 1158-1166.
Alabi, O. and J.P. O’Neill, ‘Good cancer gone bad’: a narrative review of HPV oropharyngeal cancer and potential poor outcomes. European Archives of Oto-Rhino-Laryngology, 2020. 277: p. 2185-2191.
Gribb, J.P., J.H. Wheelock, and E.S. Park, Human papilloma virus (HPV) and the current state of oropharyngeal cancer prevention and treatment. Delaware Journal of Public Health, 2023. 9(1): p. 26.
Baudouin, R., et al., Prognostic significance of the microenvironment in human papillomavirus oropharyngeal carcinoma: A systematic review. The Laryngoscope, 2024. 134(4): p. 1507-1516.
Li, J., et al., Clinical data, survival, and prognosis of 426 cases of oropharyngeal cancer: a retrospective analysis. Clinical Oral Investigations, 2023. 27(11): p. 6597-6606.
Wendt, M., et al., Long-term survival and recurrence in oropharyngeal squamous cell carcinoma in relation to subsites, HPV, and p16-status. Cancers, 2021. 13(11): p. 2553.
Ferreira, C.C., The relation between human papillomavirus (HPV) and oropharyngeal cancer: A review. PeerJ, 2023. 11: p. e15568.
Ali, K., et al., Immunohistochemical (IHC) Expression of p16 in Various Grades of Oral Squamous Cell Carcinoma (OSCC) with Snuff Use in Tertiary Care Hospitals of Peshawar: Expression of p16 in Oral Squamous Cell Carcinoma. Pakistan Journal of Health Sciences, 2024. 5(04): p. 109-115.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
